---
title: MDR Article 61: Clinical Evaluation Requirements Decoded for Startups
description: MDR Article 61 is the heart of clinical evaluation. Here is the article decoded paragraph by paragraph, with what each requirement actually means for startups.
authors: Tibor Zechmeister, Felix Lenhard
category: Clinical Evaluation & Investigations
primary_keyword: MDR Article 61 clinical evaluation
canonical_url: https://zechmeister-solutions.com/en/blog/mdr-article-61-clinical-evaluation-requirements
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# MDR Article 61: Clinical Evaluation Requirements Decoded for Startups

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **MDR Article 61 is the core clinical evaluation provision of Regulation (EU) 2017/745. It obliges manufacturers to demonstrate conformity with the relevant general safety and performance requirements on the basis of clinical data providing sufficient clinical evidence, to follow a defined and methodologically sound procedure set out in Annex XIV Part A, and to keep the clinical evaluation current throughout the life of the device using data from post-market clinical follow-up under Annex XIV Part B. The article runs from paragraph 1 to paragraph 12, and every paragraph carries a specific obligation that startups either honour deliberately or violate by accident.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- Article 61(1) establishes the basic obligation: conformity with the relevant general safety and performance requirements must be based on clinical data providing sufficient clinical evidence. The manufacturer specifies and justifies the level of evidence, taking into account the characteristics of the device and its intended purpose.
- Article 61(2) and Annex XIV Part A require a defined, methodologically sound procedure built around a clinical evaluation plan, a literature appraisal, an evaluation of clinical investigation results, and consideration of alternative treatment options.
- Article 61(3) requires the clinical evaluation and its documentation to be updated throughout the life of the device using PMCF data. For Class III and implantable devices the clinical evaluation report is updated at least annually.
- Article 61(4) sets the rule that implantable and Class III devices must undergo clinical investigation, and paragraphs (5) and (6) carve the narrow exemptions that MDCG 2023-7 clarifies in practical detail.
- Articles 61(7) through 61(9) address the clinical evaluation plan content and the role of the expert panels and competent authorities for certain implantables and Class III devices.
- Article 61(10) is the narrow escape valve where clinical data is not deemed appropriate. It is not a shortcut and Notified Bodies scrutinise its use carefully.
- Article 61(11) establishes that the clinical evaluation report is part of the technical documentation under Annex II and Annex III.
- Article 61(12) links clinical evaluation to post-market surveillance by requiring the clinical evaluation to be updated with PMCF data throughout the lifecycle.

---

## Why decode Article 61 paragraph by paragraph

Most founders who open the MDR for the first time skim Article 61, conclude that it says "you need clinical evidence," and go back to reading about classification. That skim is the source of more expensive mistakes than any other single habit in early-stage MedTech regulatory strategy. Article 61 is twelve paragraphs long. Each paragraph is a separate obligation. Each obligation interacts with Annex XIV Part A, Annex XIV Part B, and the MDCG guidance documents in specific ways. Missing one paragraph can cost a certification cycle.

This post walks through the paragraphs in the order they appear in the consolidated text of Regulation (EU) 2017/745. For each paragraph we cover three things: what the text actually says, what the text actually means in practice for a startup, and the common misreading that causes the expensive mistake. At the end, the Subtract to Ship angle and a Reality Check bring the twelve paragraphs back into one operational view.

For the pillar introduction to clinical evaluation as a whole, see [What Is Clinical Evaluation Under MDR?](/blog/what-is-clinical-evaluation-under-mdr). This post is the article-level deep dive that sits underneath it.

## Paragraphs 61(1) to 61(3). Scope, procedure, and lifecycle updating

### Article 61(1). The basic obligation

Paragraph 1 establishes that confirmation of conformity with the relevant general safety and performance requirements under the conditions of normal use of the device, and the evaluation of undesirable side-effects and of the acceptability of the benefit-risk ratio, shall be based on clinical data providing sufficient clinical evidence. The manufacturer specifies and justifies the level of clinical evidence necessary to demonstrate conformity, taking into account the characteristics of the device and its intended purpose.

**What it means for startups.** The level of clinical evidence is not a fixed quantity. It is a function of the specific device and the specific intended purpose. A Class I device built on a well-established measurement principle needs less clinical evidence than a novel implantable. The manufacturer decides, documents, and defends the level. That decision is the single highest-leverage judgement call in clinical evaluation strategy.

**Common misreading.** "The Notified Body tells us how much evidence we need." They do not. They review the sufficiency of the evidence the manufacturer specifies. If you arrive without a specified and justified level, you have already lost the argument.

### Article 61(2). The defined and methodologically sound procedure

Paragraph 2 requires the clinical evaluation to follow a defined and methodologically sound procedure based on a critical evaluation of the relevant scientific literature currently available relating to the safety, performance, design characteristics and intended purpose of the device; a critical evaluation of the results of all available clinical investigations, taking due consideration of whether the investigations were carried out under Articles 62 to 80 and Annex XV; and a consideration of currently available alternative treatment options for that purpose, if any.

**What it means for startups.** Three inputs. Literature. Investigations (yours and others'). Alternative treatments. All three must be addressed in the clinical evaluation. "We reviewed some papers" is not a procedure. A procedure is pre-specified appraisal criteria, reproducible search methods, documented exclusion logic, and a traceable argument from the data to the conformity claim. Annex XIV Part A spells out the structural elements.

**Common misreading.** Skipping the alternative-treatments analysis. Article 61(2) requires it explicitly, and Notified Bodies do notice when it is missing.

### Article 61(3). Lifecycle updating

Paragraph 3 requires the clinical evaluation and its documentation to be updated throughout the life cycle of the device concerned with clinical data obtained from the implementation of the manufacturer's PMCF plan in accordance with Annex XIV Part B and the post-market surveillance plan referred to in Article 84. For Class III devices and implantable devices, the clinical evaluation report is updated at least annually with data from the PMCF.

**What it means for startups.** The clinical evaluation report is not a one-shot document. For Class III and implantables, the update cadence is annual and binding. For lower-risk devices, the cadence is defined in the PMS and PMCF plans, proportionate to the risk and novelty. A startup that treats the CER as a pre-market deliverable only is setting up a PMS audit failure.

**Common misreading.** "We will worry about updates after CE marking." The update process has to be designed before CE marking because the PMCF plan is part of the technical documentation submitted for conformity assessment.

## Paragraphs 61(4) to 61(6). Implantables, Class III, and the narrow exemptions

### Article 61(4). The general rule for implantables and Class III

Paragraph 4 establishes that in the case of implantable devices and Class III devices, clinical investigations shall be performed, except if it is duly justified to rely on existing clinical data alone. The duly justified exception is then scoped by paragraphs 5 and 6.

**What it means for startups.** If you are building an implantable or Class III device, the default is that you will run a clinical investigation under EN ISO 14155:2020+A11:2024 and MDR Annex XV. The exceptions exist but they are narrow.

**Common misreading.** Reading paragraph 4 and assuming the investigation requirement is negotiable. For genuinely novel implantables and Class III devices it is not. Paragraphs 5 and 6 are not generic escape hatches.

### Article 61(5). Modifications to a device already marketed by the same manufacturer

Paragraph 5 allows a manufacturer of a device that has been modified from a predecessor device placed on the market by the same manufacturer to not perform a new clinical investigation, provided the manufacturer has duly justified relying on the clinical data of the predecessor device, the justification is supported by sufficient clinical evidence and is in compliance with the relevant common specifications where applicable.

**What it means for startups.** If you are a serial device manufacturer iterating on your own prior CE-marked device, you can potentially carry the prior clinical data forward. The iteration must be modest, the equivalence argument must be tight, and the clinical data of the predecessor must be sufficient. This paragraph applies to very few startups because most startups do not have a prior marketed predecessor to iterate from.

**Common misreading.** Treating "modified version" as loose. It is not. The modifications must not materially change the clinical performance or safety profile, or the predecessor data will not carry.

### Article 61(6). Equivalence to another manufacturer's device and well-established technologies

Paragraph 6 contains two sub-cases. Paragraph 61(6)(a) allows reliance on clinical data of an equivalent device marketed by another manufacturer, subject to the condition that the two manufacturers have a contract in place that explicitly allows the manufacturer of the second device full access on an ongoing basis to the technical documentation of the first device, and that the original clinical evaluation has been performed in compliance with the requirements of the Regulation. Paragraph 61(6)(b) allows reliance on existing clinical data without a new clinical investigation for specific well-established technologies. Sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors. Where the clinical evaluation is based on sufficient clinical data and is in compliance with the relevant product-specific common specifications where such common specifications are available.

**What it means for startups.** MDCG 2023-7 (December 2023) is the authoritative guidance on how 61(4) through 61(6) are interpreted in practice, including what "sufficient levels of access" means under 61(6)(a). Equivalence under MDR is significantly stricter than it was under the Directives, and the ongoing contract requirement is not a formality. It is a legal condition for the pathway to work at all. MDCG 2020-5 (April 2020) is the equivalence interpretation guide that sits alongside MDCG 2023-7 for the general equivalence case; MDCG 2023-7 refines the implantable and Class III application.

**Common misreading.** Assuming you can claim equivalence to a competitor device without a contract. You cannot, for implantables and Class III under MDCG 2023-7, and the Notified Body will reject the claim on first review.

## Paragraphs 61(7) to 61(9). The clinical evaluation plan and expert panel involvement

Article 61(7) requires, in cases where the demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, that any such exception is based on the manufacturer's risk management and on consideration of the specifics of the device-body interaction, the intended clinical performance and the claims of the manufacturer. Paragraphs (8) and (9) address the specific procedural hooks for Class III implantables and Class IIb active devices intended to administer or remove a medicinal product, where consultation with expert panels under Article 106 is required for certain high-risk devices as part of the clinical evaluation consultation procedure (CECP) defined elsewhere in the Regulation and in Annex IX.

**What it means for startups.** These paragraphs apply almost exclusively to high-risk devices where the scrutiny procedure and expert panel consultation come into play. For a founder building a Class I or Class IIa device, the operational impact of 61(7) through 61(9) is limited. For a founder building a novel Class III implantable, these paragraphs mean the clinical evaluation plan has to be written knowing that expert panels may see it, and that the defensibility bar is higher than for a routine Notified Body review.

**Common misreading.** Assuming the clinical evaluation consultation procedure is a rubber stamp. It is not. Expert panels look hard at the methodology and the data.

## Paragraphs 61(10) to 61(11). Sufficient clinical evidence and technical documentation

### Article 61(10). The narrow escape valve

Paragraph 10 is the paragraph founders reach for when they hope to avoid clinical data altogether. It states that where the demonstration of conformity with general safety and performance requirements based on clinical data is not deemed appropriate, adequate justification for any such exception shall be given based on the results of the manufacturer's risk management and on consideration of the specifics of the device-body interaction, the clinical performance intended and the claims of the manufacturer. In such cases, the adequacy of the demonstration of conformity with the general safety and performance requirements by performance evaluation, bench testing and pre-clinical evaluation alone has to be duly substantiated in the technical documentation referred to in Annex II.

**What it means for startups.** Article 61(10) exists. It is not a loophole. And we would not use that word for a regulated product anyway, because the framing is dangerous. It is a narrow, duly-substantiated, risk-argued exception for a small class of devices where clinical data genuinely cannot inform the conformity argument. Notified Bodies scrutinise 61(10) justifications harder than almost any other part of the technical file, because the paragraph is the single most misused provision in the entire clinical evaluation chapter.

**Common misreading.** "Article 61(10) lets us skip clinical evaluation." It does not. It allows, in narrow substantiated cases, the demonstration of conformity to proceed without clinical data being the primary evidence source. Not to skip the clinical evaluation, which is still required by 61(1). The distinction is subtle and matters.

### Article 61(11). The CER in the technical documentation

Paragraph 11 establishes that the clinical evaluation, its results and the clinical evidence derived from it shall be documented in a clinical evaluation report as referred to in Section 4 of Annex XIV, which, except for custom-made devices, shall be part of the technical documentation referred to in Annexes II and III relating to the device concerned.

**What it means for startups.** The CER is not a standalone deliverable. It lives inside the Annex II technical documentation and links to the Annex III PMS documentation. Every cross-reference that the Notified Body follows during review passes through this paragraph. If your technical file does not treat the CER as an integral part, the review will find gaps.

**Common misreading.** Keeping the CER in a separate folder with weak links to the rest of the technical file. The Notified Body reads the file as a whole.

## Paragraph 61(12). The link to post-market surveillance

Paragraph 12 closes the article by linking clinical evaluation back to PMS. It establishes that the results of the clinical evaluation and the clinical evidence on which it is based shall be updated throughout the life cycle of the device concerned with clinical data obtained from the implementation of the manufacturer's PMCF plan in accordance with Annex XIV Part B and the post-market surveillance plan referred to in Article 84. The paragraph reinforces 61(3) and ties the clinical evaluation into the broader PMS system of Articles 83 to 86.

**What it means for startups.** The clinical evaluation never ends. PMCF data flows in, the CER is updated, the risk management file under EN ISO 14971:2019+A11:2021 is updated, the benefit-risk ratio is re-assessed. The loop runs for the full lifecycle. For a startup, this means the PMCF plan has to be real, not aspirational. The post-market activities described in the plan must be the activities the company can actually fund and execute.

**Common misreading.** Writing a PMCF plan full of activities the company cannot afford, because the plan "looks thorough." The first PMS audit will expose the gap.

## The Graz story in one Article 61 walk-through

A company in Graz came to us with a device built on two established measurement methods. Their first plan was two or three clinical investigations under EN ISO 14155:2020+A11:2024, about EUR 400,000-500,000, about 1-1.5 years.

We walked through Article 61 paragraph by paragraph. Paragraph 1: specify the level of clinical evidence needed, given the intended purpose and the device characteristics. Paragraph 2: build the procedure around literature first, because the established measurement methods had substantial published support and harmonised standards carrying presumption of conformity. Paragraph 4: the device was not a Class III implantable, so the 61(4) default did not apply. Paragraph 10: not invoked. We still had clinical data in the form of literature, so the narrow 61(10) escape was not needed. Paragraph 11: the CER was built into the Annex II technical documentation from day one. Paragraph 12: the PMCF plan was sized to what the company could actually run after CE marking.

The literature-led clinical evaluation held up. The Notified Body accepted it. The company saved EUR 400,000-500,000 and 1-1.5 years. Not by avoiding Article 61, but by reading every paragraph carefully and building the strategy around what the paragraphs actually required rather than around the founder's first instinct.

## The Subtract to Ship angle. Article 61 as a subtraction instrument

Article 61 is not a checklist of things to add to the project. Read in the Subtract to Ship spirit, it is a subtraction instrument.

Paragraph 1 lets you subtract every piece of clinical evidence that does not map to a specific relevant general safety and performance requirement. Because the paragraph obliges you to specify and justify the level of evidence, not the maximum. Paragraph 2 lets you subtract every data source that is not literature, investigations, or alternative treatment analysis. Because the procedure only requires those three. Paragraph 3 lets you subtract every post-market activity that does not feed the CER update cycle. Because the paragraph binds updating to PMCF data under Annex XIV Part B. Paragraphs 4 through 6 let you subtract new clinical investigations where a defined exemption under MDCG 2023-7 legitimately applies. Paragraph 10 lets you subtract clinical-data-dominated arguments in the narrow substantiated cases where they are not appropriate. Never to reduce work, only where the substantiation genuinely holds.

The Subtract to Ship Evidence Pass walks this subtraction in the order of Article 61 itself. See [The Subtract to Ship Framework for MDR Compliance](/blog/subtract-to-ship-framework-mdr) for the four-pass methodology the Evidence Pass sits inside.

## Reality Check. Where do you stand on Article 61?

1. Can you quote Article 61(1) and state, in one paragraph, what level of clinical evidence you have specified for your device and how you have justified it?
2. Does your clinical evaluation procedure address all three inputs required by Article 61(2). Literature, available clinical investigations, and alternative treatment options. Or only one or two of them?
3. For Class III and implantable devices, does your PMCF schedule produce a CER update at least annually as required by Article 61(3)?
4. If your device is Class III or implantable, have you read MDCG 2023-7 and determined whether Article 61(5), 61(6)(a), or 61(6)(b) can be invoked in your case?
5. If you are claiming equivalence under Article 61(6)(a), do you have the ongoing contractual access to the other manufacturer's technical documentation that the paragraph requires?
6. If you are planning to invoke Article 61(10), have you written the risk-based substantiation that the paragraph requires and had it reviewed by someone who has seen Notified Bodies reject 61(10) claims?
7. Is the CER integrated into the Annex II technical documentation as Article 61(11) requires, or is it a separate document with weak cross-references?
8. Does your PMCF plan under Article 61(12) describe activities the company can actually fund, or does it describe activities the company hopes to fund?
9. For every piece of clinical evidence in your plan, can you name the specific paragraph of Article 61 it traces to?
10. When you last reviewed your clinical evaluation, did you subtract a piece of evidence that did not trace to a specific requirement, or did you only add?

## Frequently Asked Questions

**What does MDR Article 61(1) actually require?**
Article 61(1) requires the manufacturer to base the demonstration of conformity with the relevant general safety and performance requirements on clinical data providing sufficient clinical evidence, and to specify and justify the level of clinical evidence needed based on the characteristics of the device and its intended purpose. The paragraph places the responsibility for defining sufficiency on the manufacturer, not on the Notified Body.

**Does Article 61 require every device to run a clinical investigation?**
No. Article 61(4) establishes a default clinical investigation requirement only for implantable devices and Class III devices, and paragraphs 61(5) and 61(6) define narrow exemptions even within that group. For devices that are neither implantable nor Class III, Article 61 allows clinical evaluation built from literature, equivalence, and other clinical data sources without a new clinical investigation, provided sufficient clinical evidence under Article 61(1) can be demonstrated.

**What is Article 61(10) and when can it be used?**
Article 61(10) is the narrow provision that allows, in duly substantiated cases, the demonstration of conformity with the general safety and performance requirements to proceed without clinical data being the primary evidence source, based on risk management results, device-body interaction specifics, intended clinical performance, and manufacturer claims. It is not a shortcut. Notified Bodies scrutinise 61(10) invocations carefully and reject most of them because the substantiation does not meet the bar.

**What is the difference between Article 61 and Annex XIV?**
Article 61 sets the legal obligations and the scope of clinical evaluation. Annex XIV Part A spells out the procedural content. The clinical evaluation plan structure, the data appraisal method, the analysis method, and the CER structure. Annex XIV Part B spells out the PMCF requirements that feed back into the clinical evaluation. Article 61 is the "what" and Annex XIV is the "how."

**How often must the clinical evaluation report be updated under Article 61?**
Article 61(3) requires the clinical evaluation and documentation to be updated throughout the lifecycle using PMCF data. For Class III and implantable devices, the CER is updated at least annually. For other classes, the update frequency is defined in the PMS and PMCF plans, proportionate to risk and novelty. Never "never."

**Is MDCG 2023-7 binding?**
MDCG guidance documents are not legally binding in the strict sense, but they represent the agreed interpretation of the Medical Device Coordination Group and are treated as authoritative by Notified Bodies and competent authorities. For Article 61(4) to 61(6) applications, MDCG 2023-7 (December 2023) is the reference every review will check against.

**Does Article 61 apply to legacy devices under the Directives?**
Article 61 applies from the point the device is placed on the market under MDR. Legacy devices that remain on the market under the transitional provisions of Regulation (EU) 2023/607 continue under the previous clinical evaluation rules until they transition to MDR, at which point the full Article 61 framework applies.

## Related reading

- [What Is Clinical Evaluation Under MDR?](/blog/what-is-clinical-evaluation-under-mdr) – the pillar post for the clinical evaluation cluster and the starting point for this deep dive.
- [MDR Article 10 Manufacturer Obligations](/blog/mdr-article-10-manufacturer-obligations) – the article that sits upstream of Article 61 and frames all manufacturer duties.
- [MDR Article 52 Conformity Assessment Routes](/blog/mdr-article-52-conformity-assessment) – how clinical evaluation feeds the conformity assessment the Notified Body runs.
- [Sufficient Clinical Evidence Under MDR](/blog/sufficient-clinical-evidence-mdr) – the companion post on how to decide when clinical evidence is actually sufficient.
- [Clinical Evaluation Plan Template and Walkthrough](/blog/clinical-evaluation-plan-template) – the Annex XIV Part A plan structure in operational detail.
- [Equivalence Under MDR and MDCG 2020-5](/blog/equivalence-under-mdr) – the equivalence pathway that Article 61(6)(a) points to.
- [MDCG 2023-7 Exemptions from Clinical Investigation](/blog/mdcg-2023-7-exemptions-clinical-investigation) – the guidance document walkthrough for Article 61(4)-(6).
- [Post-Market Clinical Follow-Up Under Annex XIV Part B](/blog/pmcf-annex-xiv-part-b) – the PMCF side of the Article 61(3) and 61(12) lifecycle loop.
- [MDR Article 83 Post-Market Surveillance System](/blog/mdr-article-83-post-market-surveillance) – the PMS system the clinical evaluation feeds into.
- [MDR Article 84 Post-Market Surveillance Plan](/blog/mdr-article-84-post-market-surveillance-plan) – the PMS plan referenced in Article 61(3) and 61(12).
- [The Subtract to Ship Framework for MDR Compliance](/blog/subtract-to-ship-framework-mdr) – the four-pass methodology and the Evidence Pass this post applies to Article 61.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 61 paragraphs (1) through (12), Annex XIV Part A (clinical evaluation), Annex XIV Part B (post-market clinical follow-up). Official Journal L 117, 5.5.2017, consolidated text including Regulation (EU) 2023/607.
2. MDCG 2020-5. Clinical Evaluation. Equivalence: A guide for manufacturers and notified bodies, April 2020.
3. MDCG 2023-7. Guidance on exemptions from the requirement to perform clinical investigations pursuant to Article 61(4)-(6) MDR and on 'sufficient levels of access' to data needed to justify claims of equivalence, December 2023.
4. EN ISO 14155:2020 + A11:2024. Clinical investigation of medical devices for human subjects. Good clinical practice.
5. EN ISO 14971:2019 + A11:2021. Medical devices. Application of risk management to medical devices.

---

*This post is part of the Clinical Evaluation & Clinical Investigations cluster in the Subtract to Ship: MDR blog, sitting under the pillar post on clinical evaluation fundamentals. Authored by Felix Lenhard and Tibor Zechmeister. Article 61 is twelve paragraphs long and every paragraph carries an obligation. Decoding them carefully is the difference between a clinical evaluation that survives Notified Body review and one that does not.*

---

*This post is part of the [Clinical Evaluation & Investigations](https://zechmeister-solutions.com/en/blog/category/clinical-evaluation) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*